NYU Grossman School of Medicine, Department of Internal Medicine, New York, NY.
NYU Langone Health, Perlmutter Cancer Center, department of Pathology, New York, NY.
Clin Lung Cancer. 2022 Jan;23(1):e1-e4. doi: 10.1016/j.cllc.2021.05.011. Epub 2021 Jun 12.
Patients with one form of cancer are at increased risk for another, and this is true for lung cancer, where synchronous primary lung cancers are an increasing multifaceted challenge. Here, we present the case of a middle age woman who was found to have bilateral lung masses. Biopsy and subsequent testing revealed unique synchronous lung adenocarcinomas, each with unique genetic signatures. Despite having two unique tumors, she was found to have CHEK2 mutations in both tumors and in germline testing. Because of this extensive testing that showed unique tumors, she was ultimately diagnosed with stage IIIb and IA2 lung cancers, and this changed her treatment options. Consideration of unique primary tumors leads to thorough diagnostics, which changed this patient's diagnosis, prognosis, and treatment. We hope this case raises awareness for multiple primary tumors, as well as CHEK2 as an important oncogene.
患有一种癌症形式的患者患另一种癌症的风险增加,这对于肺癌来说也是如此,其中同时性原发性肺癌是一个日益复杂的挑战。在这里,我们介绍了一位中年女性的病例,她被发现患有双侧肺肿块。活检和随后的检查显示出独特的同步肺腺癌,每个都具有独特的遗传特征。尽管有两个独特的肿瘤,但在两个肿瘤和种系测试中均发现了 CHEK2 突变。由于广泛的测试显示出独特的肿瘤,最终诊断为 IIIb 期和 IA2 期肺癌,这改变了她的治疗选择。对独特原发性肿瘤的考虑导致了彻底的诊断,这改变了患者的诊断、预后和治疗。我们希望这个病例能引起对多原发性肿瘤以及 CHEK2 作为重要致癌基因的关注。